BINEX Co. Ltd (053030) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of BINEX Co. Ltd stock KRW 1,844, price KRW 6,800, that is 72.9% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
BINEX Co. Ltd
053030 · KQFar too expensive (fair value 73% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range 5,740 KRW – 27,000 KRW · fair‑value band 794.01 KRW – 2,895 KRW · the 6,800 KRW price screens above the 1,844 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether BINEX Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea.
Show moreShow less
It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products.
BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
Stock analysis
BINEX Co. Ltd (053030) currently trades at 6,800 KRW, while our model-based Fair Value estimate is 1,844 KRW, 73% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the data coverage at low.
Scenario range: 794.01 KRW (bear) to 2,895 KRW (bull), the price of 6,800 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BINEX Co. Ltd reported revenue of 168B KRW in FY2025 versus 134B KRW in FY2021, a compound +5.8%/yr. Reported net income was −3.2B KRW in FY2025.
Key figures
Market cap 217B KRW (≈ $163M) Micro · P/S ratio 1.26 · Net margin 10.7% · Return on equity −1,423% · Return on assets (EBIT) −0.1% (5-year average) · Operating margin 14.7% · Revenue (TTM) 155B KRW · Revenue growth (YoY) +18.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).
What moves the price
The share trades about 59% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −73%, 053030 screens richer than that median.
Fair Value models
All 2 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
053030 screens overvalued: fair value 73% below the price. Compare with ST Pharm Co →
Compare BINEX Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Huons Global Co 084110 | 18,970 KRW | 47,019 KRW | +148% | vs 053030 |
| DongKook Pharmaceutical Co 086450 | 24,800 KRW | 28,372 KRW | +14% | vs 053030 |
| VIKRAMTH VIKRAMTH | ₹332.55 | ₹352.17 | +6% | vs 053030 |
| ST Pharm Co 237690 | 71,000 KRW | 61,182 KRW | −14% | vs 053030 |
| Vivozon Pharmaceutical Co 082800 | 2,780 KRW | 2,179 KRW | −22% | vs 053030 |
| Oscotec Inc 039200 | 32,750 KRW | 21,262 KRW | −35% | vs 053030 |
| NatureCell Co 007390 | 21,800 KRW | 11,176 KRW | −49% | vs 053030 |
| Mezzion Pharma Co 140410 | 63,800 KRW | 31,450 KRW | −51% | vs 053030 |
| Caregen Co 214370 | 26,850 KRW | 5,414 KRW | −80% | vs 053030 |
| SHUKRAPHAR SHUKRAPHAR | ₹82.25 | ₹9.14 | −89% | vs 053030 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is BINEX Co. Ltd (053030) overvalued or undervalued?
What is the fair value of 053030?
What is the quality score of 053030?
What is the price target for BINEX Co. Ltd (053030)?
What is the BINEX Co. Ltd stock forecast for 2026?
What is the revenue of BINEX Co. Ltd (053030)?
What is the intrinsic value of BINEX Co. Ltd (053030)?
Is BINEX Co. Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 053030?
How much is BINEX Co. Ltd worth?
What do the bullish and bearish scenarios say about 053030?
How solid is the balance sheet of BINEX Co. Ltd (053030)?
How far is 053030 from its 52-week high?
Which stocks are comparable to BINEX Co. Ltd?
Is BINEX Co. Ltd stock attractive at the current price?
How is the fair value of 053030 calculated?
Is it still worth investing in stocks now?
What is the share price of BINEX Co. Ltd (053030)?
What should I pay attention to with BINEX Co. Ltd right now?
Key figures of BINEX Co. Ltd
How large is the market capitalisation of BINEX Co. Ltd (053030)?
What is the P/S ratio of BINEX Co. Ltd (053030)?
What is the net margin of BINEX Co. Ltd (053030)?
What is the return on equity of BINEX Co. Ltd (053030)?
What is the EBIT return on assets of BINEX Co. Ltd (053030)?
What is the operating margin of BINEX Co. Ltd (053030)?
How fast is revenue growing at BINEX Co. Ltd (053030)?
How fast are earnings growing at BINEX Co. Ltd (053030)?
How much free cash flow does BINEX Co. Ltd (053030) generate?
How much net debt does BINEX Co. Ltd (053030) carry?
Watch BINEX Co. Ltd in the live analysis
One click puts BINEX Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.